Compare Altria Group Inc (MO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Zimmer Biomet Holdings Inc — how do they compare? Altria Group Inc trades at $68.11 (market cap $113.36B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Altria Group Inc is far larger — about 6.3× Zimmer Biomet Holdings Inc's market cap, and Altria Group Inc pays the higher dividend (6.54%). Which is the better fit depends on your goals.
| MO | ZBH | |
|---|---|---|
Market Cap | $113.36B | $18.05B |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $104.26 |
52-Week Low | $54.72 | $79.58 |
Enterprise Value | $135.57B | $25.11B |
Dividend Yield | 6.54% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MO trades at $68.18, down 1.02% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing revenue expectations, and maintains a strong 6.4% dividend yield after its 57th consecutive annual increase. Cash flow from operations remains robust at $9.29 billion for 2025, supporting dividend sustainability despite regulatory headwinds.
Outlook is cautiously optimistic with a consensus price target of $68.50, reflecting Wall Street's buy-heavy ratings. Key risks include ongoing FDA litigation, declining cigarette volumes, and high debt levels. The stock offers income appeal but faces secular challenges in the tobacco industry, requiring careful monitoring of regulatory developments and smoke-free segment growth.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
